Mahzi Therapeutics
Raising nowOperatingMahzi Therapeutics Inc.
Healthcare · San Mateo, CA
Advancing precision genetic therapies for rare neurodevelopment diseases with no treatments
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Pre-money — the valuation set before each round’s money came inBlue bars are the pre-money valuation the company stated for a priced round.
Fundraising history
Team
10 people
Biotech pioneer. 20+ years in executive leadership in rare disease and pharmaceutical roles at Merck, Ultragenyx & Genzyme. Contributed to 4 FDA approvals including Januvia & Gardasil. Hebrew University MD. Weizmann Institute Molecular Biology PhD.
Finance maven . 20+ years in rare disease biotech. SVP Corporate Strategy & VP FP&A at Ultragenyx (10+ yrs). Director FP&A, BioMarin. CFO, Mahzi Therapeutics. Dartmouth College BA.
Manufacturing titan. Built Audentes' AAV GMP facility in 9 months. Led build-out of $100M commercial gene therapy plant in just 16 months. Key CMC role in $3B Astellas acquisition. Managed 250 FTEs, $180M budget. Stanford Chemical Engineering BS & MS.
Endpoint architect. Key contributor to Crysvita FDA approval for XLH. 10+ years designing clinical outcome assessments for rare diseases. Ex Ultragenyx & Genentech. Ohio State University Psychology BS. Brown T32 and Stanford Pediatric Psychology Fellow.
Operations wizard . 22+ years in drug development. Clinical ops lead for 2 FDA/EMA approvals: Crysvita (XLH) & Kanuma (LAL Deficiency). Ex Ultragenyx, Synageva, Annexon. Boston University Psychology BA. UMass Nursing BSN, Summa Cum Laude.
Regulatory veteran. 27+ years experience at Pfizer, GSK, Shire, AstraZeneca, Sanofi & BridgeBio. Led global submissions for rare disease & gene therapy approvals. Managed FDA Advisory Committee meetings. University of Maryland Animal Sciences BS.
Clinical strategist. 10+ years advancing rare disease programs from preclinical to Phase 3. Gene therapy, biologics & small molecule dev. Ex Pfizer, Edgewise, Actio. Secured ODD & Fast Track designations. Cambridge Medical Sciences MA. UCL MD. Durham MBA.
Show 1 more personShow fewer
Names and titles as disclosed on WeFunder, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.